Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma

I. Trávníček, J. Branžovský, K. Kalusová, O. Hes, L. Holubec, KB. Pele, T. Ürge, M. Hora,

. 2015 ; 35 (10) : 5661-5666.

Language English Country Greece

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT12010 MZ0 CEP Register

AIM: To identify tissue biomarkers that are predictive of the therapeutic effect of sunitinib in treatment of metastatic clear cell renal cell carcinoma (mCRCC). MATERIALS AND METHODS: Our study included 39 patients with mCRCC treated with sunitinib. Patients were stratified into two groups based on their response to sunitinib treatment: non-responders (progression), and responders (stable disease, regression). The effect of treatment was measured by comparing imaging studies before the initiation treatment with those performed at between 3rd and 7th months of treatment, depending on the patient. Histological samples of tumor tissue and healthy renal parenchyma, acquired during surgery of the primary tumor, were examined with immunohistochemistry to detect tissue targets involved in the signaling pathways of tumor growth and neoangiogenesis. We selected mammalian target of rapamycine, p53, vascular endothelial growth factor, hypoxia-inducible factor 1 and 2 and carbonic anhydrase IX. We compared the average levels of biomarker expression in both, tumor tissue, as well as in healthy renal parenchyma. Results were evaluated using the Student's t-test. RESULTS: For responders, statistically significant differences in marker expression in tumor tissue versus healthy parenchyma were found for mTOR (4%/16.7%; p=0.01031), p53 (4%/12.7%; p=0.042019), VEGF (62.7%/45%; p=0.019836) and CAIX (45%/15.33%; p=0.001624). A further significant difference was found in the frequency of high expression (more than 60%) between tumor tissue and healthy parenchyma in VEGF (65%/35%; p=0.026487) and CAIX (42%/8%; p=0.003328). CAIX was expressed at high levels in the tumor tissue in both evaluated groups. CONCLUSION: A significantly higher expression of VEGF in CRCC in comparison to healthy parenchyma can predict a better response to sunitinib.

000      
00000naa a2200000 a 4500
001      
bmc16009947
003      
CZ-PrNML
005      
20241120101115.0
007      
ta
008      
160408s2015 gr f 000 0|engg|
009      
AR
035    __
$a (PubMed)26408740
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Trávníček, Ivan $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic travniceki@fnplzen.cz. $7 xx0227802
245    10
$a Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma / $c I. Trávníček, J. Branžovský, K. Kalusová, O. Hes, L. Holubec, KB. Pele, T. Ürge, M. Hora,
520    9_
$a AIM: To identify tissue biomarkers that are predictive of the therapeutic effect of sunitinib in treatment of metastatic clear cell renal cell carcinoma (mCRCC). MATERIALS AND METHODS: Our study included 39 patients with mCRCC treated with sunitinib. Patients were stratified into two groups based on their response to sunitinib treatment: non-responders (progression), and responders (stable disease, regression). The effect of treatment was measured by comparing imaging studies before the initiation treatment with those performed at between 3rd and 7th months of treatment, depending on the patient. Histological samples of tumor tissue and healthy renal parenchyma, acquired during surgery of the primary tumor, were examined with immunohistochemistry to detect tissue targets involved in the signaling pathways of tumor growth and neoangiogenesis. We selected mammalian target of rapamycine, p53, vascular endothelial growth factor, hypoxia-inducible factor 1 and 2 and carbonic anhydrase IX. We compared the average levels of biomarker expression in both, tumor tissue, as well as in healthy renal parenchyma. Results were evaluated using the Student's t-test. RESULTS: For responders, statistically significant differences in marker expression in tumor tissue versus healthy parenchyma were found for mTOR (4%/16.7%; p=0.01031), p53 (4%/12.7%; p=0.042019), VEGF (62.7%/45%; p=0.019836) and CAIX (45%/15.33%; p=0.001624). A further significant difference was found in the frequency of high expression (more than 60%) between tumor tissue and healthy parenchyma in VEGF (65%/35%; p=0.026487) and CAIX (42%/8%; p=0.003328). CAIX was expressed at high levels in the tumor tissue in both evaluated groups. CONCLUSION: A significantly higher expression of VEGF in CRCC in comparison to healthy parenchyma can predict a better response to sunitinib.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x mortalita $x sekundární $7 D002292
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunoenzymatické techniky $7 D007124
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a ledviny $x metabolismus $x patologie $7 D007668
650    _2
$a nádory ledvin $x farmakoterapie $x mortalita $x patologie $7 D007680
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a míra přežití $7 D015996
650    _2
$a čipová analýza tkání $x metody $7 D046888
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Branžovský, Jindřich, $d 1987- $u Department of Pathology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $7 xx0324720
700    1_
$a Procházková, Kristýna, $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $d 1982- $7 xx0227765
700    1_
$a Hes, Ondřej, $u Department of Pathology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $d 1968- $7 jn20001103502
700    1_
$a Holubec, Luboš, $d 1972- $7 xx0068645 $u Department of Oncology and Radiotherapy, Faculty Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Pele, Kevin Bauleth $u Department of Pathology, Faculty Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Ürge, Tomáš $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $7 xx0092825
700    1_
$a Hora, Milan, $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $d 1967- $7 mzk2004258359
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 35, č. 10 (2015), s. 5661-5666
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26408740 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20241120101110 $b ABA008
999    __
$a ok $b bmc $g 1113376 $s 934315
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 35 $c 10 $d 5661-5666 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
GRA    __
$a NT12010 $p MZ0
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...